Genethon, the French pioneer in the discovery and development of gene therapies for rare diseases, and Ampersand Biomedicines, a Flagship Pioneering multi-product platform company developing smarter ...
The CHOP's research team findings support the hypothesis that rare AAV integration can contribute to human oncogenesis, which ...
USP recognizes CryoTEM for characterizing empty/full/intermediate capsids on AAV8 reference standards STOCKHOLM, ...
Dyno Therapeutics launches two new AAV capsids and AI platform for rare disease therapeutic development at ASGCT 2026 ...
Dyno Therapeutics launches two new AAV Capsids, AI platform for rare disease therapeutic development
Dyno Therapeutics launches two new AAV Capsids, AI platform for rare disease therapeutic development: Watertown, Massachusetts Saturday, May 16, 2026, 13:00 Hrs [IST] Dyno Therape ...
Recombinant adeno-associated virus (AAV) vectors are predominantly nonintegrating, but rare genomic integration events have been associated with oncogenesis in neonatal murine models. Here we ...
Oral presentation at ASGCT showcases breakthrough technology enabling precise in vivo genome editing in the CNS using a ...
Dyno Therapeutics to Present New Capsids and AI Advancements in Gene Delivery at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting Company to host a Scientific Symposium, present ...
Genethon, Ampersand Biomedicines partner to design novel AAV vectors with enhanced tissue specificity for effective tolerated gene therapies: France Saturday, May 23, 2026, 16:00 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results